SCHEMBL16336195

SCHEMBL16336195

CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1Nc1ccc(CCN(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MELK Q14680 19/20 1.00
▸ DYRK1A Q13627 2/20 0.68
▸ BMPR1B O00238 1/20 0.60
▸ PLK4 O00444 1/20 0.60
▸ CIT O14578 1/20 0.60
▸ AURKA O14965 1/20 0.60
▸ GAK O14976 1/20 0.60
▸ EPHB6 O15197 1/20 0.60
▸ RIPK2 O43353 1/20 0.60
▸ ERN1 O75460 1/20 0.60
▸ RPS6KA5 O75582 1/20 0.60
▸ RPS6KA4 O75676 1/20 0.60
▸ STK16 O75716 1/20 0.60
▸ STK10 O94804 1/20 0.60
▸ PRKD3 O94806 1/20 0.60
▸ MAP3K6 O95382 1/20 0.60
▸ MAP4K4 O95819 1/20 0.60
▸ LATS1 O95835 1/20 0.60
▸ PAK4 O96013 1/20 0.60
▸ ABL1 P00519 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30626735 1.00 MELK (1.00) MELKDYRK1ABMPR1BPLK4CIT
Hydrochloric Acid SCHEMBL16337915 0.99 MELK (0.98) MELKDYRK1ABMPR1BPLK4CIT
SCHEMBL16336817 0.95 MELK (1.00) MELKDYRK1A
Hydrochloric Acid SCHEMBL16337989 0.94 MELK (0.98) MELKDYRK1A
SCHEMBL16369197 0.94 MELK (0.88) MELKDYRK1A
SCHEMBL16338112 0.93 MELK (1.00) MELKDYRK1A
SCHEMBL30626720 0.93 MELK (1.00) MELKDYRK1A
Hydrochloric Acid SCHEMBL17260530 0.92 MELK (0.98) MELKDYRK1A
SCHEMBL16338189 0.85 MELK (1.00) MELKDYRK1ABMPR1BPLK4CIT
SCHEMBL30626706 0.85 MELK (1.00) MELKDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2753329-B1 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS ONCOTHERAPY SCIENCE INC (JP) 2017-08-09 — — EP claimed
US-9345709-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2016-05-24 — — US claimed
US-20150328225-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-11-19 — — US claimed
US-9067937-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-06-30 — — US claimed
US-20150005302-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-01-01 — — US claimed
US-20230301973-A1 TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA FLOHIL JACOB ARY (NL) 2023-09-28 — — US disclosed
WO-2018106118-A1 TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA FLOHIL JACOB ARY (NL) 2018-06-14 — — WO disclosed
EP-2753329-B1 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS ONCOTHERAPY SCIENCE INC (JP) 2017-08-09 — — EP disclosed
US-9345709-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2016-05-24 — — US disclosed
US-9345709-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2016-05-24 — — US disclosed
US-9345709-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2016-05-24 — — US disclosed
US-20150328225-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-11-19 — — US disclosed
US-20150328225-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-11-19 — — US disclosed
US-20150328225-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-11-19 — — US disclosed
US-9067937-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-06-30 — — US disclosed
US-9067937-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-06-30 — — US disclosed
US-9067937-B2 1,5-naphthyridine derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-06-30 — — US disclosed
US-20150005302-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-01-01 — — US disclosed
US-20150005302-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-01-01 — — US disclosed
US-20150005302-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2015-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150328225-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NEK1, NEK5 MELK 1/4885DYRK1A 1584/4885BMPR1B 2446/4885
US-20230301973-A1 TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA ABCC2, SLC2A2, ABCB1 MELK 13/4885DYRK1A 173/4885BMPR1B 2312/4885
US-20150005302-A1 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NEK1, NEK5 MELK 1/4885DYRK1A 1584/4885BMPR1B 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback